Related Experiment Videos

Statin therapy and clinical outcomes in heart failure: a propensity-matched analysis

Maral Ouzounian1, Jack V Tu, Peter C Austin

  • 1Heart & Stroke/Richard Lewar Centre for Excellence, University of Toronto, Toronto, Ontario, Canada.

Journal of Cardiac Failure
|March 31, 2009
PubMed

Insights

Statin therapy shows improved outcomes for heart failure (HF) patients, especially those with coronary artery disease (CAD). This study analyzed 5-year survival rates and combined endpoints in HF patients post-hospitalization.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Statin therapy's role in heart failure (HF) is a significant area of research.
  • Previous studies have yielded varied results regarding statin efficacy in HF patients.

Purpose of the Study:

  • To investigate the association between statin therapy and patient outcomes after hospitalization for heart failure.
  • To determine if statins improve mortality and morbidity in HF patients.

Main Methods:

  • Utilized data from 6,451 heart failure patients hospitalized in Ontario between 1999-2001.
  • Employed propensity score methods to analyze 5-year outcomes, stratifying by coronary artery disease (CAD) and ejection fraction (HFPEF/HFREF).

Main Results:

  • Statin use was linked to a significant 5-year mortality benefit overall (HR 0.85, P = .05).
  • Patients with coronary artery disease (CAD) showed a pronounced benefit from statins, with reduced mortality (HR 0.79, P = .008) and a lower risk of combined endpoints (HR 0.85, P = .045).

Conclusions:

  • Statin therapy is associated with improved outcomes in heart failure patients discharged from hospital.
  • The benefits of statins were particularly evident in patients with co-existing coronary artery disease (CAD).
  • Ejection fraction status did not significantly alter the impact of statin therapy in this heart failure cohort.
Abstract

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...